<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181005041243N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-08</date_registration>
      <primary_sponsor>Iranian academic center for education culture and research</primary_sponsor>
      <public_title>Therapeutic effect of ointment containing extract of Arbenia Euchromia plant and amniotic membrane in burn wound</public_title>
      <acronym></acronym>
      <scientific_title>Assessing therapeutic effects of a topical ointment containing the extract of Arnebia euchroma and amniotic membrane in patients with burn; a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-09-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/77665</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Allocation of individuals to groups is done in the form of random allocation in blocks of four. In this way, first the volume of each block is specified (block of four), then the list of blocks is specified with the help of www.randomizer.org and numbers are assigned to them (numbers 1 to 15 for 60 people) and each of the numbers with the list of treatment specific to you is placed in an envelope. Then, the people included in the research randomly select envelopes containing numbers between 1 and 15, and the allocation of people to two groups 1 and 2 is determined based on the list of four blocks of each number, Blinding description: A label is placed on the can containing the drug and 1% silver sulfadiazine. The number 1 or 2 is written on the sticker of the can containing medicine (extract) and the number 1 or 2 is written on the label of the can containing 1% silver sulfadiazine. Other specifications included on the said labels are completely the same. The patient and other people are unaware of the nature and meaning of the numbers 1 and 2 on the label. The place of blinding is in the research institute.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Burn wound.</hc_freetext>
      <i_freetext>Intervention group: Ointment name: Arnebia euchroma, chemical composition and its concentration: extracts are prepared by soaking plant materials in (67%-EtOH) under ultrasound at room temperature. The extracts will be filtered through Whatman No. 1 filter paper, and then the filtrates were successively combined and concentrated under vacuum by a rotary evaporator. Then, in a special mill, the dry extract will be mixed with the oily base composition and it will be kept for 73 hours in a special tank in the dark at a temperature of 37 degrees Celsius. The final product is sterilized by gamma radiation (23 kg). Dosage: In both groups, after washing the burn wound with 0.9% sterile saline solution, the wound is placed in the vicinity of the open air for 5 minutes until its surface is completely dry, then using a sterile water hose to complete the measurements. The surface of the burn wound should be covered with a thickness of 3 mm, ointment number 1 or 2 is applied to the wound, and a layer of sterile gauze is placed on the wound. Wound dressings are changed daily for up to 14 days..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as the information related to the main outcome, can be shared. All information will be published in the form of a work report and finally a scientific article. If you need all the data, it is possible for the person in charge of the plan to provide the information without patients being identifiable.

When:
The access period starts immediately after the results are printed

To whom:
Only researchers working in academic and scientific institutions

Conditions:
The data will only be given to researchers who are researching the same topic.

Where to obtain:
Responsible for the project: Dr. Maryam Nasimi
Address: Razi Hospital, Vahdat Eslami St.
Number: 09128435986
Email: nsm.maryam@gmail.com

How to obtain:
After sending a reasonable request to the person in charge of the project by email, if the conditions are met, the information will be shared with them.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Maryam Nasimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi Hospital, Vahdate eslami St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>11996 63911</zip>
        <telephone>+98 21 5563 0553</telephone>
        <email>nsm.maryam@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Maryam Nasimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi Hospital, Vahdate eslami St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>11996 63911</zip>
        <telephone>+98 21 5563 0553</telephone>
        <email>nsm.maryam@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age between 18-60
Burns due to contact with hot liquids or heat sources, patients with second degree burns according to the criteria determined according to the reference sources as follows: 1. The surface of the burn is red or pink in color. 2- It has a moist surface with liquid oozing or accompanied by blisters. 3- Having extreme sensitivity when touching
The extent of the burn wound is between 1 and 10%, which is determined based on the criteria of Lund and Browder
Less than 6 hours should pass from the occurrence of the burn to the time the patient goes to the treatment center
The patient's wound was free of infection and trauma
The wound of the patient should be only on the limbs and trunk and not in the head, face and genital area.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Suffering from diseases such as anemia, diabetes, malignancies and immune system defects due to the impact on the wound healing process.
Taking drugs that weaken the immune system and are effective on wound healing, such as steroid drugs - substance abuse
The patient's unwillingness to continue participating in the research or not returning to the treatment center
Damage to the burn wound during the intervention, chemotherapy or radiation therapy during the research and showing signs of sensitivity to 1% silver sulfadiazine or the study drug during the intervention
pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ointment name: Arnebia euchroma, chemical composition and its concentration: extracts are prepared by soaking plant materials in (67%-EtOH) under ultrasound at room temperature. The extracts will be filtered through Whatman No. 1 filter paper, and then the filtrates were successively combined and concentrated under vacuum by a rotary evaporator. Then, in a special mill, the dry extract will be mixed with the oily base composition and it will be kept for 73 hours in a special tank in the dark at a temperature of 37 degrees Celsius. The final product is sterilized by gamma radiation (23 kg). Dosage: In both groups, after washing the burn wound with 0.9% sterile saline solution, the wound is placed in the vicinity of the open air for 5 minutes until its surface is completely dry, then using a sterile water hose to complete the measurements. The surface of the burn wound should be covered with a thickness of 3 mm, ointment number 1 or 2 is applied to the wound, and a layer of sterile gauze is placed on the wound. Wound dressings are changed daily for up to 14 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining the extent of the wound and the time required to heal the wound. Timepoint: At the beginning of the study (before the start of the intervention) and 14 days after starting to use ointments. Method of measurement: The size of the wound is determined by a ruler and the time required to heal the wound is determined by a doctor's visit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Edema; hematoma; itching; pain; infection. Timepoint: At the beginning of the study (before the start of the intervention) and 14 days after starting to use ointments. Method of measurement: doctor's opinion.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iranian academic center for education culture and research</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-06-26</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Ghods St., Keshavarz Blvd, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
